429 related articles for article (PubMed ID: 37686080)
1. The Bidirectional Interplay of α-Synuclein with Lipids in the Central Nervous System and Its Implications for the Pathogenesis of Parkinson's Disease.
Battis K; Xiang W; Winkler J
Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37686080
[TBL] [Abstract][Full Text] [Related]
2. Alpha-Synuclein and Lipids: The Elephant in the Room?
Sarchione A; Marchand A; Taymans JM; Chartier-Harlin MC
Cells; 2021 Sep; 10(9):. PubMed ID: 34572099
[TBL] [Abstract][Full Text] [Related]
3. Effects of α-Synuclein-Associated Post-Translational Modifications in Parkinson's Disease.
He S; Wang F; Yung KKL; Zhang S; Qu S
ACS Chem Neurosci; 2021 Apr; 12(7):1061-1071. PubMed ID: 33769791
[TBL] [Abstract][Full Text] [Related]
4. Alpha synuclein post translational modifications: potential targets for Parkinson's disease therapy?
Brembati V; Faustini G; Longhena F; Bellucci A
Front Mol Neurosci; 2023; 16():1197853. PubMed ID: 37305556
[TBL] [Abstract][Full Text] [Related]
5. Phosphorylation of α-Synuclein at Y125 and S129 alters its metal binding properties: implications for understanding the role of α-Synuclein in the pathogenesis of Parkinson's Disease and related disorders.
Lu Y; Prudent M; Fauvet B; Lashuel HA; Girault HH
ACS Chem Neurosci; 2011 Nov; 2(11):667-75. PubMed ID: 22860160
[TBL] [Abstract][Full Text] [Related]
6. The involvement of α-synucleinopathy in the disruption of microglial homeostasis contributes to the pathogenesis of Parkinson's disease.
Miao Y; Meng H
Cell Commun Signal; 2024 Jan; 22(1):31. PubMed ID: 38216911
[TBL] [Abstract][Full Text] [Related]
7. Role of post-translational modifications in modulating the structure, function and toxicity of alpha-synuclein: implications for Parkinson's disease pathogenesis and therapies.
Oueslati A; Fournier M; Lashuel HA
Prog Brain Res; 2010; 183():115-45. PubMed ID: 20696318
[TBL] [Abstract][Full Text] [Related]
8. Exploring the Roles of Post-Translational Modifications in the Pathogenesis of Parkinson's Disease Using Synthetic and Semisynthetic Modified α-Synuclein.
Chen H; Zhao YF; Chen YX; Li YM
ACS Chem Neurosci; 2019 Feb; 10(2):910-921. PubMed ID: 30628768
[TBL] [Abstract][Full Text] [Related]
9. Role of post-translational modifications on the alpha-synuclein aggregation-related pathogenesis of Parkinson's disease.
Yoo H; Lee J; Kim B; Moon H; Jeong H; Lee K; Song WJ; Hur JK; Oh Y
BMB Rep; 2022 Jul; 55(7):323-335. PubMed ID: 35733294
[TBL] [Abstract][Full Text] [Related]
10. Neurotoxic conversion of beta-synuclein: a novel approach to generate a transgenic mouse model of synucleinopathies?
Fujita M; Sekigawa A; Sekiyama K; Sugama S; Hashimoto M
J Neurol; 2009 Aug; 256 Suppl 3():286-92. PubMed ID: 19711118
[TBL] [Abstract][Full Text] [Related]
11. The interplay between parkin and alpha-synuclein; possible implications for the pathogenesis of Parkinson's disease.
Jęśko H; Lenkiewicz AM; Wilkaniec A; Adamczyk A
Acta Neurobiol Exp (Wars); 2019; 79(3):276-289. PubMed ID: 31587020
[TBL] [Abstract][Full Text] [Related]
12. Lipids: Key Players That Modulate α-Synuclein Toxicity and Neurodegeneration in Parkinson's Disease.
Mori A; Imai Y; Hattori N
Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32392751
[TBL] [Abstract][Full Text] [Related]
13. α-Synuclein misfolding and aggregation: Implications in Parkinson's disease pathogenesis.
Mehra S; Sahay S; Maji SK
Biochim Biophys Acta Proteins Proteom; 2019 Oct; 1867(10):890-908. PubMed ID: 30853581
[TBL] [Abstract][Full Text] [Related]
14. Lipid vesicles affect the aggregation of 4-hydroxy-2-nonenal-modified α-synuclein oligomers.
Sardar Sinha M; Villamil Giraldo AM; Öllinger K; Hallbeck M; Civitelli L
Biochim Biophys Acta Mol Basis Dis; 2018 Sep; 1864(9 Pt B):3060-3068. PubMed ID: 29960040
[TBL] [Abstract][Full Text] [Related]
15. An Update on the Critical Role of α-Synuclein in Parkinson's Disease and Other Synucleinopathies: from Tissue to Cellular and Molecular Levels.
Serratos IN; Hernández-Pérez E; Campos C; Aschner M; Santamaría A
Mol Neurobiol; 2022 Jan; 59(1):620-642. PubMed ID: 34750787
[TBL] [Abstract][Full Text] [Related]
16. NK cells clear α-synuclein and the depletion of NK cells exacerbates synuclein pathology in a mouse model of α-synucleinopathy.
Earls RH; Menees KB; Chung J; Gutekunst CA; Lee HJ; Hazim MG; Rada B; Wood LB; Lee JK
Proc Natl Acad Sci U S A; 2020 Jan; 117(3):1762-1771. PubMed ID: 31900358
[TBL] [Abstract][Full Text] [Related]
17. Intermediates of α-synuclein aggregation: Implications in Parkinson's disease pathogenesis.
Gadhe L; Sakunthala A; Mukherjee S; Gahlot N; Bera R; Sawner AS; Kadu P; Maji SK
Biophys Chem; 2022 Feb; 281():106736. PubMed ID: 34923391
[TBL] [Abstract][Full Text] [Related]
18. Interaction of Alpha-Synuclein With Lipids: Mitochondrial Cardiolipin as a Critical Player in the Pathogenesis of Parkinson's Disease.
Gilmozzi V; Gentile G; Castelo Rueda MP; Hicks AA; Pramstaller PP; Zanon A; Lévesque M; Pichler I
Front Neurosci; 2020; 14():578993. PubMed ID: 33122994
[TBL] [Abstract][Full Text] [Related]
19. Post-translational modifications of soluble α-synuclein regulate the amplification of pathological α-synuclein.
Zhang S; Zhu R; Pan B; Xu H; Olufemi MF; Gathagan RJ; Li Y; Zhang L; Zhang J; Xiang W; Kagan EM; Cao X; Yuan C; Kim SJ; Williams CK; Magaki S; Vinters HV; Lashuel HA; Garcia BA; James Petersson E; Trojanowski JQ; Lee VM; Peng C
Nat Neurosci; 2023 Feb; 26(2):213-225. PubMed ID: 36690898
[TBL] [Abstract][Full Text] [Related]
20. Alpha-synuclein in Parkinson's disease and other synucleinopathies: from overt neurodegeneration back to early synaptic dysfunction.
Calabresi P; Mechelli A; Natale G; Volpicelli-Daley L; Di Lazzaro G; Ghiglieri V
Cell Death Dis; 2023 Mar; 14(3):176. PubMed ID: 36859484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
